

Sinclair Pharma plc
("Sinclair Pharma" or the "Company")

VCP grants

The Company is pleased to announce that the following directors and PDMRs have been granted units under the Company's Value Creation Plan ("VCP"):

Name	Title	Number of VCP Units	Percentage of total VCP Units
Chris Spooner	CEO	3,500	35.0%
Christophe Foucher	COO	2,500	25.0%
Simon Youlton	Chief Scientific Officer	500	5.0%
Alan Olby	CFO	450	4.5%
Steve Redman	Legal Director	450	4.5%

The VCP was approved by shareholders at the Company's general meeting held on 13 January 2011 and full details of the VCP were set out in the circular to shareholders that incorporated the notice of the meeting.

No payment has been made for the grant of these awards and the VCP units have no value at grant but have the potential to convert into awards of nil-cost options. The VCP units entitle participants to share in 15% of the return created for shareholders above a hurdle, measured at five annual measurements dates over the VCP plan period. VCP units will only convert to awards of nil-cost options if the annual hurdle of approximately 20% is achieved.

50% of any nil-cost options granted will become exercisable on the fifth measurement date with the remaining 50% of the options exercisable on the first anniversary of this date.

For further information, please contact:

Sinclair Pharma plc

Grahame Cook, Chairman

Penny Freer, Chairman of Remuneration Committee

Tel: +44 (0)1483 410 600

Singer Capital Markets Limited

Shaun Dobson

Claes Spång

Tel: +44 (0)20 3205 7500

Disclosure requirements required under the Takeover Code (the "Code")

Under Rule 8.3(a) of the Code, any person who is interested in 1% or more of any class of relevant securities of an offeree company or of any paper offeror (being any offeror other than an offeror in respect of which it has been announced that its offer is, or is likely to be, solely in cash) must make an Opening Position Disclosure following the commencement of the offer period and, if later, following the announcement in which any paper offeror is first identified. An Opening Position Disclosure must contain details of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any paper offeror(s). An Opening Position Disclosure by a person to whom Rule 8.3(a) applies must be made by no later than 3.30 pm (London time) on the 10th business day following the commencement of the offer period and, if appropriate, by no later than 3.30 pm (London time) on the 10th business day following the announcement in which any paper offeror is first identified.

Relevant persons who deal in the relevant securities of the offeree company or of a paper offeror prior to the deadline for making an Opening Position Disclosure must instead make a Dealing Disclosure.

Under Rule 8.3(b) of the Code, any person who is, or becomes, interested in 1% or more of any class of relevant securities of the offeree company or of any paper offeror must make a Dealing Disclosure if the person deals in any relevant securities of the offeree company or of any paper offeror. A Dealing Disclosure must contain details of the dealing concerned and of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any paper offeror, save to the extent that these details have previously been disclosed under Rule 8. A Dealing Disclosure by a person to whom Rule 8.3(b) applies must be made by no later than 3.30 pm (London time) on the business day following the date of the relevant dealing.

If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire or control an interest in relevant securities of an offeree company or a paper offeror, they will be deemed to be a single person for the purpose of Rule 8.3.

Opening Position Disclosures must also be made by the offeree company and by any offeror and Dealing Disclosures must also be made by the offeree company, by any offeror and by any persons acting in concert with any of them (see Rules 8.1, 8.2 and 8.4).

Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Takeover Panel's website at www.thetakeoverpanel.org.uk, including details of the number of relevant securities in issue, when the offer period commenced and when any offeror was first identified. If you are in any doubt as to whether you are required to make an Opening Position Disclosure or a Dealing Disclosure, you should contact the Panel's Market Surveillance Unit on +44 (0)20 7638 0129.

Rule 2.10 Disclosure

In accordance with Rule 2.10 of the Code, Sinclair Pharma plc ("Company") has 240,979,560 ordinary shares of 1p each in issue with ISIN GB0033856740.

Publication on websites

In accordance with Rule 19.11 of the Code, a copy of this announcement will be published, subject to certain restrictions relating to persons resident in restricted jurisdictions, on Sinclair Pharma's website at www.sinclairpharma.com. For the avoidance of doubt, the contents of this website is not incorporated into and does not form part of this announcement.